Lactobacillus Reuteri Overview

Summary of Lactobacillus Reuteri Research

Lactobacillus reuteri is a gut microbe that has been extensively studied for its role in vertebrate symbiosis, influencing the host's biology, ecology, and evolution. Research has focused on its mutualistic relationships and the mechanisms of interaction with vertebrate hosts.

Key Insights

• L. reuteri's ecological and evolutionary strategies in the gut microbiome provide insights into host-microbe interactions.
• Understanding microbial symbiosis in vertebrate guts could offer strategies for manipulating the microbiome to improve health.
• L. reuteri has shown effectiveness in displacing harmful bacteria and reducing inflammation, which could be used to develop functional foods.
• Maternal supplementation with L. reuteri can influence the presence of the bacteria in infants' feces and breast milk.
• Probiotic strains like L. reuteri may contribute to oral health by preventing dental caries, periodontal disease, and bad breath.
• L. reuteri supplementation can improve skin and hair health, possibly through immune responses involving interleukin-10 and oxytocin levels.
• Genomic analysis has revealed L. reuteri's capability to produce health-promoting substances, including antimicrobial agents and vitamins.
• The oral administration of L. reuteri can promote regulatory T cells development, which may mitigate allergic reactions.
• L. reuteri's presence in the gastrointestinal tract alters immune responses and may suppress bone resorption and loss associated with estrogen deficiency.
• Clinical trials have studied L. reuteri's role in preventing and treating conditions like gastrointestinal infections, cystic fibrosis, and bacterial vaginosis.

Conclusions

Studies suggest that L. reuteri has numerous health benefits, including modulation of the immune system, prevention of infection, and support of overall health. Its potential in therapeutic applications for various diseases and conditions makes it a significant focus for future research.

References:

1. Host-microbial symbiosis in the vertebrate gastrointestinal tract and the Lactobacillus reuteri paradigm
2. Role of dietary lactobacilli in gastrointestinal microecology
3. Role of probiotics in health and disease: a review
4. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production
5. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli
6. Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life
7. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession
8. Salivary IgA response to probiotic bacteria and mutans streptococci after the use of chewing gum containing Lactobacillus reuteri
9. Influence of dietary supplementation with Lactobacillus reuteri on the oral flora of healthy subjects
10. Probiotic bacteria induce a 'glow of health'
11. Exploring metabolic pathway reconstruction and genome-wide expression profiling in Lactobacillus reuteri to define functional probiotic features
12. A catalog of reference genomes from the human microbiome
13. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice
14. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats
15. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract
16. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study
17. Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread
18. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938
19. Persistence of Lactobacillus reuteri DSM17938 in the human intestinal tract: response to consecutive and alternate-day supplementation
20. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults
21. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial
22. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study
23. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women
24. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women
25. Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans
26. Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats
27. Characterization of reutericyclin produced by Lactobacillus reuteri LTH2584
28. Inducible gene expression in Lactobacillus reuteri LTH5531 during type II sourdough fermentation
29. Complete genome sequence of Lactobacillus reuteri I5007, a probiotic strain isolated from healthy piglet
30. Identification of Lactobacillus reuteri genes specifically induced in the mouse gastrointestinal tract
31. Global transcriptional response of Lactobacillus reuteri to the sourdough environment
32. The probiotic paradox: live and dead cells are biological response modifiers
33. Anti-inflammatory effect of bioflora probiotic administered orally or subcutaneously with live or dead bacteria
34. Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria
35. The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups
36. Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri
37. Lactobacillus reuteri DSM 20016 produces cobalamin-dependent diol dehydratase in metabolosomes and metabolizes 1,2-propanediol by disproportionation
38. The First Low Molecular Weight Antibiotic from Lactic Acid Bacteria: Reutericyclin, a New Tetramic Acid
39. Chemical modulation of the biological activity of reutericyclin: a membrane-active antibiotic from Lactobacillus reuteri
40. Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections
41. Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations
42. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling
43. Histamine-producing pathway encoded on an unstable plasmid in Lactobacillus hilgardii 0006
44. Sequencing, characterization and transcriptional analysis of the histidine decarboxylase operon of Lactobacillus buchneri
45. Histamine suppresses gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors
46. Probiotic microbes sustain youthful serum testosterone levels and testicular size in aging mice
47. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors
48. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients
49. Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner
50. A single NFκB system for both canonical and non-canonical signaling
51. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses
52. The NF-kappaB family of transcription factors and its regulation
53. The IKK complex, a central regulator of NF-kappaB activation
54. Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression
55. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling
56. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus
57. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization
58. Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress
59. Molecular analysis of the composition of the bifidobacterial and lactobacillus microflora of humans
60. Analysis of fecal populations of bifidobacteria and lactobacilli and investigation of the immunological responses of their human hosts to the predominant strains
61. Molecular and microbiological analysis of caecal microbiota in rats fed with diets supplemented either with prebiotics or probiotics
62. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial
63. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei
64. Antidiabetic effects of an oral administration of Lactobacillus casei in a non-insulin-dependent diabetes mellitus (NIDDM) model using KK-Ay mice
65. Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats
66. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia
67. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats
68. Advanced glycation end products and diabetic complications
69. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-κB signaling in the intestine
70. Microbial reprogramming inhibits Western diet-associated obesity
71. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals
72. Million et al "Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals." Letter to editors
73. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients
74. Changes in diet and lifestyle and long-term weight gain in women and men
75. Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice
76. Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice
77. Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model
78. Probiotics protect mice from ovariectomy-induced cortical bone loss
79. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand
80. Reciprocal interactions of the intestinal microbiota and immune system
81. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study
82. Regulatory T cells: mechanisms of differentiation and function
83. Lactobacillus reuteri DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis
84. No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy
85. Probiotics in primary prevention of allergic disease--follow-up at 8-9 years of age
86. Neuropeptidergic regulation of affiliative behavior and social bonding in animals
87. Interleukin-10: a key cytokine in depression?
88. IL-10 as a mediator in the HPA axis and brain
89. Probiotic 'glow of health': it's more than skin deep
90. Effect of xylitol on dental caries and salivary Streptococcus mutans levels among a group of mother-child pairs
91. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets
92. A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli
93. Lactobacillus reuteri in bovine milk fermented decreases the oral carriage of mutans streptococci
94. Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors
95. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children
96. Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era
97. Pathogenesis of Helicobacter pylori infection
98. Helicobacter pylori and probiotics
99. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report
100. Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial
101. Evidence of intestinal inflammation in patients with cystic fibrosis
102. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis
103. A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults
104. The diagnosis of bacterial vaginosis and vaginal flora changes
105. Probiotics for the treatment of women with bacterial vaginosis
106. Lactobacilli vs antibiotics to prevent recurrent urinary tract infections: an inconclusive, not inferior, outcome
107. The advantages of second best: comment on "Lactobacilli vs antibiotics to prevent urinary tract infections"
108. Lactobacillus casei reduces CD8+ T cell-mediated skin inflammation
109. Supplementation with oral probiotic bacteria maintains cutaneous immune homeostasis after UV exposure
110. Is there a 'gut-brain-skin axis'?
111. Acne vulgaris, probiotics and the gut-brain-skin axis: from anecdote to translational medicine
112. Lactobacillus species isolated from vaginal secretions of healthy and bacterial vaginosis-intermediate Mexican women: a prospective study
113. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species
114. Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women
115. Vaginal lactobacillus flora of healthy Swedish women
116. Vaginal microbiome of reproductive-age women
117. Reducing parenting stress in families with irritable infants
118. Paroxysmal fussing in infancy, sometimes called colic
119. Is colic a gastrointestinal disorder?
120. Intestinal microflora in breastfed colicky and non-colicky infants
121. Bacterial counts of intestinal Lactobacillus species in infants with colic
122. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial
123. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study
124. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial
125. 454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with Lactobacillus reuteri DSM 17938
126. Probiotics to improve outcomes of colic in the community: protocol for the Baby Biotics randomised controlled trial
127. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial
128. Probiotics to prevent or treat excessive infant crying: systematic review and meta-analysis
129. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial
130. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study
131. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
132. Lactobacillus reuteri ATCC55730 in cystic fibrosis
133. The complete coenzyme B12 biosynthesis gene cluster of Lactobacillus reuteri CRL1098
134. Lactobacillus reuteri CRL1098 produces cobalamin
135. Biochemistry of coenzyme B12-dependent glycerol and diol dehydratases and organization of the encoding genes
136. Functional identification in Lactobacillus reuteri of a PocR-like transcription factor regulating glycerol utilization and vitamin B12 synthesis
137. Comparative genome analysis of Lactobacillus reuteri and Lactobacillus fermentum reveal a genomic island for reuterin and cobalamin production
138. Pseudovitamin B(12) is the corrinoid produced by Lactobacillus reuteri CRL1098 under anaerobic conditions
139. Lactobacillus reuteri CRL 1098 prevents side effects produced by a nutritional vitamin B deficiency
140. The evidence that pseudovitamin B(12) is biologically active in mammals is still lacking - a comment on Molina et al.'s (2009) experimental design
141. High-Level folate production in fermented foods by the B12 producer Lactobacillus reuteri JCM1112
142. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial
143. Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study
144. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis
145. Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study
146. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea--a double-blind study

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!